Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $280.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by Morgan Stanley from $245.00 to $280.00 in a report released on Tuesday morning, Marketbeat Ratings reports. Morgan Stanley currently has an overweight rating on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Barclays raised their price target on shares of Jazz Pharmaceuticals from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Tuesday. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $188.00 to $307.00 in a report on Tuesday, May 19th. Raymond James Financial reiterated an “outperform” rating and set a $239.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Bank of America increased their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $272.74.

Jazz Pharmaceuticals Trading Down 1.9%

Shares of JAZZ stock opened at $256.65 on Tuesday. The stock has a 50 day simple moving average of $240.89 and a 200 day simple moving average of $209.19. The stock has a market cap of $16.66 billion, a P/E ratio of 17.70, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company has a current ratio of 1.78, a quick ratio of 1.85 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 1 year low of $106.65 and a 1 year high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period last year, the firm earned ($8.25) EPS. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. On average, research analysts predict that Jazz Pharmaceuticals will post 21.61 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the transaction, the director owned 9,680 shares in the company, valued at approximately $2,231,724. This represents a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rick E. Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the transaction, the director owned 9,567 shares of the company’s stock, valued at $2,311,100.19. The trade was a 22.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 19,098 shares of company stock valued at $4,649,786. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Ruffer LLP purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $2,425,000. Allianz Asset Management GmbH boosted its stake in shares of Jazz Pharmaceuticals by 68.2% during the fourth quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after purchasing an additional 242,892 shares during the period. Swedbank AB grew its holdings in Jazz Pharmaceuticals by 2.7% in the 4th quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock worth $187,506,000 after acquiring an additional 28,882 shares during the last quarter. SEB Asset Management AB bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $8,765,000. Finally, Castleark Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $9,214,000. 89.14% of the stock is currently owned by institutional investors.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo upgraded Jazz Pharmaceuticals to Buy and raised its price target to $300 from $285, adding to a broadly favorable analyst view. Jazz Pharmaceuticals Receives a Buy from Wells Fargo
• Positive Sentiment: Morgan Stanley raised its price target to $280, while Needham also forecast meaningful appreciation and maintained a bullish stance. JPMorgan separately indicated that the stock could rise, reinforcing investor confidence in JAZZ’s valuation and growth prospects. Morgan Stanley Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz’s second-quarter revenue reached $1.21 billion, exceeding the $1.11 billion consensus estimate and increasing 15.5% year over year. Management raised its 2026 revenue guidance to $4.60 billion-$4.75 billion, supported by strength in its neuroscience and oncology businesses.
• Positive Sentiment: The Xywav-led oxybate franchise continues to post double-digit growth despite generic Xyrem competition, reducing concerns about near-term erosion in Jazz’s core business. Potential FDA approval of Ziihera for first-line gastroesophageal cancer on August 25 also provides an additional catalyst.
• Neutral Sentiment: A valuation comparison with Techne highlights JAZZ as a stock investors are assessing on earnings, growth and relative value metrics, but the article does not represent a new fundamental development for Jazz Pharmaceuticals. JAZZ vs. TECH Which Stock Is the Better Value Option
• Negative Sentiment: Adjusted quarterly EPS of $5.71 missed the $6.18 consensus estimate, which could limit upside if future earnings do not keep pace with revenue growth.
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares worth about $1.52 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by only 1.64%, making it a limited signal of insider concern.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.